Nobuyoshi Kosaka
5PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jan 27, 2026
Correction: Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).Shigenori E Nagai, Masaya Hattori, Tetsuhiro Yoshinami
|Apr 05, 2025
Overall survival of palbociclib plus endocrine therapy in Japanese patients with HR+/HER2- advanced breast cancer in the first-or second-line setting: a multicenter observational study (P-BRIDGE study).Shigenori E Nagai, Masaya Hattori, Tetsuhiro Yoshinami
|Apr 20, 2024
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.Tetsuhiro Yoshinami, Shigenori E Nagai, Masaya Hattori
|Jun 20, 2020
The miR-1908/SRM regulatory axis contributes to extracellular vesicle secretion in prostate cancer.Fumihiko Urabe, Nobuyoshi Kosaka, Yurika Sawa
|Jun 05, 2020
miR-26a regulates extracellular vesicle secretion from prostate cancer cells via targeting SHC4, PFDN4, and CHORDC1.Fumihiko Urabe, Nobuyoshi Kosaka, Yurika Sawa
Pageof 1
